Commentary

Teriparatide: Label changes and identifying patients for long-term use

Paul D. Miller, MD, HDSc (HON), E. Michael Lewiecki, MD, Kelly Krohn, MD and Elliott Schwartz, MD
Cleveland Clinic Journal of Medicine September 2021, 88 (9) 489-493; DOI: https://doi.org/10.3949/ccjm.88a.21011

Article Figures & Data

Tables

  • TABLE 1

    Features of patients who may benefit from long-term teriparatide use

    Very high fracture risk, unable to come off glucocorticoid therapy
    High fracture risk, with P1NP level that remains high after 2 years on teriparatide
    High fracture risk, with multiple vertebral compression fractures at baseline but none while on teriparatide
    Adynamic renal bone disease
    Severe chronic obstructive pulmonary disease and vertebral compression fractures

    • P1NP = procollagen type 1 N-terminal propeptide

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects